183 related articles for article (PubMed ID: 29307789)
1. Inner ear involvement in Fabry disease: Clinical and audiometric evaluation of a large cohort of patients followed in a reference centre.
Rodrigues J; Azevedo O; Sousa N; Cunha D; Mexedo A; Fonseca R
Eur J Med Genet; 2018 Jun; 61(6):341-347. PubMed ID: 29307789
[TBL] [Abstract][Full Text] [Related]
2. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
[TBL] [Abstract][Full Text] [Related]
3. Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY.
Asquier-Khati A; Mauhin W; Michel G; Gendre A; Durant C; Lavigne C; Maillard H; Lacombe D; Willems M; Lidove O; Masseau A
Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1639-1644. PubMed ID: 34825971
[TBL] [Abstract][Full Text] [Related]
4. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy.
Sergi B; Conti G; Paludetti G;
Acta Otorhinolaryngol Ital; 2010 Apr; 30(2):87-93. PubMed ID: 20559478
[TBL] [Abstract][Full Text] [Related]
5. Cochleovestibular manifestations in Fabry disease: Importance of screening and systematic ENT evaluation.
Eyermann C; Raguin T; Rohmer D; Noel E; Charpiot A
Eur Ann Otorhinolaryngol Head Neck Dis; 2019 Sep; 136(4):273-279. PubMed ID: 31072727
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss in Fabry disease: data from the Fabry Outcome Survey.
Hegemann S; Hajioff D; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):654-62. PubMed ID: 16919049
[TBL] [Abstract][Full Text] [Related]
7. [Auditory and vestibular findings in Fabry disease: a study of 25 patients].
Pichon M; Lidove O; Roudaire ML; Barry B; Herman P; Gobert D; Pasqualoni E; Compain C; Chauveheid MP; Papo T
Rev Med Interne; 2012 Jul; 33(7):364-9. PubMed ID: 22365473
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease.
Köping M; Shehata-Dieler W; Cebulla M; Rak K; Oder D; Müntze J; Nordbeck P; Wanner C; Hagen R; Schraven S
PLoS One; 2017; 12(11):e0188103. PubMed ID: 29161295
[TBL] [Abstract][Full Text] [Related]
9. The hearing status in 12 female and 15 male Japanese Fabry patients.
Sakurai Y; Kojima H; Shiwa M; Ohashi T; Eto Y; Moriyama H
Auris Nasus Larynx; 2009 Dec; 36(6):627-32. PubMed ID: 19261412
[TBL] [Abstract][Full Text] [Related]
10. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females.
Conti G; Sergi B
Acta Paediatr Suppl; 2003 Dec; 92(443):33-7; discussion 27. PubMed ID: 14989464
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss.
Holy R; Hlozkova T; Prochazkova K; Kalfert D; Hybnerova F; Ebelova D; Streubel B; Chovanec M; Gal B; Linhart A; Astl J
J Appl Biomed; 2021 Mar; 19(1):57-61. PubMed ID: 34907716
[TBL] [Abstract][Full Text] [Related]
12. Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment.
Yazdanfard PD; Madsen CV; Nielsen LH; Rasmussen ÅK; Petersen JH; Seth A; Sørensen SS; Køber L; Feldt-Rasmussen U
PLoS One; 2019; 14(12):e0225071. PubMed ID: 31809513
[TBL] [Abstract][Full Text] [Related]
13. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.
Hajioff D; Enever Y; Quiney R; Zuckerman J; Mackermot K; Mehta A
J Inherit Metab Dis; 2003; 26(8):787-94. PubMed ID: 14739683
[TBL] [Abstract][Full Text] [Related]
14. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.
Hajioff D; Hegemann S; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):663-7. PubMed ID: 16919050
[TBL] [Abstract][Full Text] [Related]
15. Early detection of sensorineural hearing loss in Muckle-Wells-syndrome.
Kuemmerle-Deschner JB; Koitschev A; Tyrrell PN; Plontke SK; Deschner N; Hansmann S; Ummenhofer K; Lohse P; Koitschev C; Benseler SM
Pediatr Rheumatol Online J; 2015 Nov; 13(1):43. PubMed ID: 26531310
[TBL] [Abstract][Full Text] [Related]
16. Hearing improvement in patients with Fabry disease treated with agalsidase alfa.
Hajioff D; Goodwin S; Quiney R; Zuckerman J; MacDermot KD; Mehta A
Acta Paediatr Suppl; 2003 Dec; 92(443):28-30; discussion 27. PubMed ID: 14989462
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
18. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease.
Ries M; Kim HJ; Zalewski CK; Mastroianni MA; Moore DF; Brady RO; Dambrosia JM; Schiffmann R; Brewer CC
Brain; 2007 Jan; 130(Pt 1):143-50. PubMed ID: 17105746
[TBL] [Abstract][Full Text] [Related]
19. Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey.
Keilmann A; Hajioff D; Ramaswami U;
J Inherit Metab Dis; 2009 Dec; 32(6):739. PubMed ID: 19876760
[TBL] [Abstract][Full Text] [Related]
20. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy.
Palla A; Hegemann S; Widmer U; Straumann D
J Neurol; 2007 Oct; 254(10):1433-42. PubMed ID: 17934877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
